AGIO Agios Pharmaceuticals, Inc.

54.09
+4.26  (8.55%)
Previous Close 49.83
Open 49.86
Price To book 5.22
Market Cap 2.27B
Shares 42,014,000
Volume 1,137,186
Short Ratio 10.87
Av. Daily Volume 819,432

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
AG-120
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Updated data due 2H 2017. Pivotal trial design update due 3Q 2017.
AG-348
Pyruvate kinase deficiency
Phase 3 to be initiated 1H 2017
AG-120 and VIDAZA
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-221 - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
NDA filed December 2016.
AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 2 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
  2. Agios Pharmaceuticals 4Q Loss $1.48 Per Share
  3. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
  4. Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
  5. Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT
  6. Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
  7. Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
  8. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  9. Agios Pharmaceuticals reports 4Q loss
  10. Agios Pharmaceuticals reports 4Q loss
  11. Q4 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open
  12. Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
  13. Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
  14. Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
  15. Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017
  16. Agios Pharma upgraded by Oppenheimer
  17. Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
  18. Why Agios Pharmaceuticals Sank 34.4% in 2016
  19. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  20. Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017